Changhoon Yoo

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Robin Kate Kelley, Makoto Ueno, Changhoon Yoo et al. · The Lancet · 2023 · 891 citations · Full text

Urology, Surgical Oncology, Gastrointestinal Oncology +5

Association Between Expression Level of PD1 by Tumor-Infiltrating CD8+ T Cells and Features of Hepatocellular Carcinoma

Hyung‐Don Kim, Gi‐Won Song, Seongyeol Park et al. · Gastroenterology · 2018 · 255 citations

Cancer Immunosurveillance, Hepatology, Hepatocellular Carcinoma +7

[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

Simron Singh, Daniel Halperin, Sten Myrehaug et al. · The Lancet · 2024 · 250 citations · Full text

Grade 2–3, Endocrine Oncology, Long-acting Octreotide +10

Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study

Changhoon Yoo, Kyu‐pyo Kim, Jae Ho Jeong et al. · The Lancet Oncology · 2021 · 209 citations

Oncology, Medicine, Biliary Cancer +6

Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Min‐Hee Ryu, Changhoon Yoo et al. · The Lancet Oncology · 2013 · 184 citations

Gastrointestinal Oncology, Medicine, Pathology +5